1. To demostrate that colistin iv. is not inferior to meropenen in empiric treatment of VAP regarding the final point of primary efficacy: mortality in the 28 subsequent days.
2. To compare the security of treatment with colistin vs. meropenem in VAP.
3. To compare microbiological efficacy of treatment with colistin vs meropenen in VAP.